Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Treasury Shares (2016 - 2025)

Avalo Therapeutics filings provide 8 years of Treasury Shares readings, the most recent being $387064.0 for Q4 2025.

  • On a quarterly basis, Treasury Shares fell 38.77% to $387064.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $387064.0, a 38.77% decrease, with the full-year FY2025 number at $387064.0, down 38.77% from a year prior.
  • Treasury Shares hit $387064.0 in Q4 2025 for Avalo Therapeutics, down from $421397.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $632100.0 in Q3 2024 to a low of $11250.0 in Q4 2021.
  • Median Treasury Shares over the past 4 years was $387064.0 (2025), compared with a mean of $295420.0.
  • Biggest five-year swings in Treasury Shares: tumbled 92.78% in 2021 and later crashed 33.33% in 2025.
  • Avalo Therapeutics' Treasury Shares stood at $11250.0 in 2021, then changed by 0.0% to $11250.0 in 2022, then skyrocketed by 5518.67% to $632100.0 in 2024, then tumbled by 38.77% to $387064.0 in 2025.
  • The last three reported values for Treasury Shares were $387064.0 (Q4 2025), $421397.0 (Q3 2025), and $421397.0 (Q2 2025) per Business Quant data.